Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs?

Texto completo
Autor(es):
Markus, Regina P. [1] ; Silva, Claudia L. M. [2] ; Franco, Daiane Gil [1] ; Barbosa, Jr., Eduardo Mortani [3] ; Ferreira, Zulma S. [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Lab Chronopharmacol, Dept Physiol, Inst Biosci, BR-05508900 Sao Paulo - Brazil
[2] Univ Fed Rio de Janeiro, Inst Biomed Sci, Cellular & Mol Pharmacol Res Program, Ccs, RJ - Brazil
[3] Univ Penn, Dept Radiol, Philadelphia, PA 19104 - USA
Número total de Afiliações: 3
Tipo de documento: Artigo de Revisão
Fonte: PHARMACOLOGY & THERAPEUTICS; v. 126, n. 3, p. 251-262, JUN 2010.
Citações Web of Science: 37
Resumo

Melatonin, the darkness hormone, synchronizes several physiological functions to light/dark cycle. Besides the awake/sleep cycle that is intuitively linked to day/night, daily variations in memory acquisition and innate or acquired immune responses are some of the major activities linked to melatonin rhythm. The daily variation of these complex processes is due to changes in specific mechanisms. In the last years we focused on the influence of melatonin on the expression and function of nicotinic acetylcholine receptors (nAChRs). Melatonin, either ``in vivo{''} or ``in vitro{''}, increases, in a selective manner, the efficiency of alpha-bungarotoxin (alpha-BTX)-sensitive nAChRs. Melatonin's effect on receptors located in rat sympathetic nerve terminals. cerebellum, skeletal muscle and chick retina, was tested. We observed that melatonin is essential for the development of alpha-BTX-sensitive nAChRs, and important for receptor maintenance in aging models. Taking into account that both melatonin and alpha-7 nAChRs (one of the subtypes sensitive to alpha-BTX) are involved in the development of Alzheimer's disease, here we discuss the possibility of a therapeutic strategy focused on both melatonin replacement and its potential association with cholinergic drugs. (c) 2010 Elsevier Inc. All rights reserved. (AU)

Processo FAPESP: 02/02957-6 - Glândula pineal e melatonina - mecanismo de temporização de respostas neurais e processos inflamatórios
Beneficiário:Regina Pekelmann Markus
Linha de fomento: Auxílio à Pesquisa - Temático
Processo FAPESP: 07/07871-6 - Eixo Imune-Pineal: produção endócrina e parácrina de melatonina em condições de injúria
Beneficiário:Regina Pekelmann Markus
Linha de fomento: Auxílio à Pesquisa - Temático